600 Objective response impact on patient reported outcomes (PROs) in patients with aNSCLC with PD-L1 ≥50% receiving cemiplimab versus chemotherapy: EMPOWER-Lung 1

Bibliographic Details
Main Authors: Mustafa Ozguroglu, Saadettin Kilickap, Igor Bondarenko, Ahmet Sezer, Mahmut Gümüş, Miranda Gogishvili, Xuanyao He, Giuseppe Gullo, Petra Rietschel, Ruben GW Quek
Format: Article
Language:English
Published: BMJ Publishing Group 2023-11-01
Series:Journal for ImmunoTherapy of Cancer